45
Participants
Start Date
June 5, 2013
Primary Completion Date
February 28, 2015
Study Completion Date
July 31, 2016
Ponatinib
Ponatinib 45 mg, tablets, orally, once-daily.
Fox Chase Cancer Center, Site #012, Philadelphia
Oregon Health & Sciences University, Site #048, Portland
Massachusetts General Hospital, Site #047, Boston
Dana-Farber Cancer Institute, Site #008, Boston
Lead Sponsor
Ariad Pharmaceuticals
INDUSTRY